The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...
Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...
According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in ...
To mimic physiological insulin release, both long-acting and short-acting insulin preparations are needed. After decades of optimizations to develop longer-acting insulin preparations to reduce ...
The FDA approved its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin Tresiba (insulin degludec) got US approval late last year. [caption id ...
Trials including commercially available formulations of insulin detemir or insulin glargine were compared with NPH. Pertinent English-language clinical trials published between 2000 and 2006 were ...
In an awake individual, mild-to-moderate nocturnal hypoglycemia is easily corrected by ingesting a snack containing approximately 5 g of fast-acting carbohydrate ... the basal insulin, a bedtime ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback